How long do patents last on new drugs?
In the U.S., a drug patent typically lasts up to 20 years from the date the patent was filed, not from when the drug is approved.[1] However, the time available to market a drug under that patent can be shorter in practice because drug development and approval take years.
Why does drug “patent life” seem shorter than 20 years?
Even though the patent term is 20 years from filing, new drugs usually spend many years in clinical trials and the regulatory review process before they can be marketed. That delay reduces the amount of the patent term left to earn exclusivity after approval.[1]
What else can extend market protection beyond a drug patent?
In the U.S., patents can be supplemented by additional exclusivity programs tied to regulatory approval, such as:
- Patent term adjustments (to compensate for certain patent-office delays)
- Patent term extensions (for certain regulatory review delays)
These mechanisms can add time beyond the basic 20-year term, depending on the situation.[1]
Do “patent” and “exclusivity” mean the same thing?
No. Patents are legal rights granted to inventors/holders and typically run on a patent-term clock. Regulatory exclusivity is separate and can protect a drug from certain approvals even after a patent expires. The exact timeline depends on the specific drug and the mix of patents and regulatory exclusivity it has.
What about outside the U.S.?
Patent term rules vary by country, but many jurisdictions also use a 20-year-from-filing framework, with local adjustments and extensions.
When do generic or biosimilar competitors usually enter?
Generic entry timing depends on when relevant patents and/or regulatory exclusivity end for that specific product. The key is not just “the patent,” but which patents cover the drug (active ingredient, formulation, methods of use, etc.) and whether any exclusivity periods apply.
Sources
[1] https://www.uspto.gov/patents/search/patent-term-and-patent-expiration